In a report released on May 15, David Risinger from SVB Securities reiterated a Buy rating on HilleVax, Inc (HLVX – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $13.85.
Risinger covers the Healthcare sector, focusing on stocks such as Halozyme, Centessa Pharmaceuticals, and Eli Lilly & Co. According to TipRanks, Risinger has an average return of 6.6% and a 55.28% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HilleVax, Inc with a $26.00 average price target, which is an 87.73% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $22.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
HLVX market cap is currently $544.9M and has a P/E ratio of -3.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Read More on HLVX:
- HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
- HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
- HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
- HilleVax reports Q4 EPS (56c), consensus ($1.46)
